Kyverna Therapeutics (NASDAQ:KYTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Kyverna Therapeutics (NASDAQ:KYTX) from a sell rating to a hold rating in a report released on Saturday morning.

A number of other equities research analysts have also commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. JPMorgan Chase & Co. lowered their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, HC Wainwright upped their price target on shares of Kyverna Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Friday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Kyverna Therapeutics Trading Down 11.6%

Shares of KYTX opened at $9.49 on Friday. The firm has a market cap of $576.90 million, a price-to-earnings ratio of -2.89 and a beta of 2.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.15. Kyverna Therapeutics has a fifty-two week low of $2.06 and a fifty-two week high of $13.67. The firm has a 50 day moving average price of $9.05 and a 200-day moving average price of $8.38.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. As a group, equities research analysts forecast that Kyverna Therapeutics will post -2.74 earnings per share for the current year.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in Kyverna Therapeutics by 106.6% in the 1st quarter. Renaissance Technologies LLC now owns 367,492 shares of the company’s stock worth $3,171,000 after purchasing an additional 189,593 shares in the last quarter. Walleye Capital LLC bought a new position in Kyverna Therapeutics in the 1st quarter worth $330,000. AIGH Capital Management LLC raised its holdings in Kyverna Therapeutics by 33.3% in the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock worth $17,260,000 after purchasing an additional 500,000 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Kyverna Therapeutics in the 1st quarter worth $991,000. Finally, Wesbanco Bank Inc. bought a new position in Kyverna Therapeutics in the 1st quarter worth $952,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.